Cullinan Oncology, Inc.

NASDAQ (USD): Cullinan Oncology, Inc. (CGEM)

Last Price

16.81

Today's Change

-2.21 (11.61%)

Day's Change

16.78 - 18.92

Trading Volume

1,320,716

Overview

Market Cap

968 Million

Shares Outstanding

57 Million

Avg Volume

848,938

Avg Price (50 Days)

22.38

Avg Price (200 Days)

14.62

PE Ratio

-5.37

EPS

-3.13

Earnings Announcement

08-Aug-2024

Previous Close

19.02

Open

18.52

Day's Range

16.78 - 18.92

Year Range

7.64 - 30.189

Trading Volume

1,338,212

Price Change Highlight

1 Day Change

-11.62%

5 Day Change

-21.78%

1 Month Change

-27.45%

3 Month Change

8.45%

6 Month Change

83.12%

Ytd Change

58.73%

1 Year Change

28.62%

3 Year Change

-35.42%

5 Year Change

-43.80%

10 Year Change

-43.80%

Max Change

-43.80%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment